# A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)

> **NCT06964165** · PHASE2 · TERMINATED · sponsor: **Tesaro, Inc.** · enrollment: 36 (actual)

## Conditions studied

- Ovarian Neoplasms

## Interventions

- **DRUG:** Niraparib
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT06964165
- **Lead sponsor:** Tesaro, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-14
- **Primary completion:** 2024-06-28
- **Final completion:** 2025-03-31
- **Target enrollment:** 36 (ACTUAL)
- **Why stopped:** The study stopped after meeting pre-specified futility criteria
- **Last updated:** 2025-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06964165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06964165, "A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06964165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*